Elevance Health (NYSE:ELV) Stock: Insider Ratnakar Lavu Sells 1,300 Shares

Elevance Health, Inc. (NYSE:ELV) EVP Ratnakar Lavu sold 1,300 shares of Elevance Health stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $440.00, for a total value of $572,000.00. Following the transaction, the executive vice president owned 14,849 shares of the company’s stock, valued at $6,533,560. The trade was a 8.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Elevance Health Stock Performance

Shares of ELV traded down $5.83 during mid-day trading on Friday, reaching $426.17. The company had a trading volume of 1,443,875 shares, compared to its average volume of 1,597,887. Elevance Health, Inc. has a 52-week low of $274.84 and a 52-week high of $450.69. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $92.08 billion, a P/E ratio of 18.17, a PEG ratio of 2.07 and a beta of 0.63. The stock has a 50 day moving average of $412.38 and a two-hundred day moving average of $373.28.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, topping the consensus estimate of $4.71 by $2.28. The firm had revenue of $50.44 billion for the quarter, compared to analyst estimates of $49.28 billion. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. Elevance Health’s revenue for the quarter was up .7% compared to the same quarter last year. During the same period last year, the company earned $6.03 earnings per share. On average, analysts expect that Elevance Health, Inc. will post 29.16 earnings per share for the current year.

Elevance Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be issued a $1.72 dividend. The ex-dividend date of this dividend is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. Elevance Health’s payout ratio is presently 29.34%.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
• Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
• Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
• Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.

Analysts Set New Price Targets

ELV has been the subject of a number of research reports. Royal Bank Of Canada upped their target price on shares of Elevance Health from $424.00 to $455.00 and gave the stock a “sector perform” rating in a report on Thursday, October 22nd. Wells Fargo & Company lifted their target price on shares of Elevance Health from $473.00 to $492.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 27th. Mizuho set a $490.00 target price on shares of Elevance Health in a report on Friday, October 23rd. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, Guggenheim raised their price target on shares of Elevance Health from $460.00 to $485.00 and gave the stock a “buy” rating in a report on Thursday, October 22nd. Fifteen research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, Elevance Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $456.48.

Institutional Trading of Elevance Health

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Field & Main Bank grew its holdings in shares of Elevance Health by 1.3% in the 2nd quarter. Field & Main Bank now owns 1,883 shares of the company’s stock worth $728,000 after acquiring an additional 25 shares during the period. Simplicity Wealth LLC raised its holdings in Elevance Health by 1.3% during the third quarter. Simplicity Wealth LLC now owns 1,939 shares of the company’s stock worth $754,000 after purchasing an additional 25 shares during the last quarter. Tranquilli Financial Advisor LLC raised its holdings in Elevance Health by 1.3% during the second quarter. Tranquilli Financial Advisor LLC now owns 2,081 shares of the company’s stock worth $805,000 after purchasing an additional 26 shares during the last quarter. Mather Group LLC. raised its holdings in Elevance Health by 3.5% during the third quarter. Mather Group LLC. now owns 766 shares of the company’s stock worth $298,000 after purchasing an additional 26 shares during the last quarter. Finally, 55 North Private Wealth LLC boosted its position in Elevance Health by 4.5% during the third quarter. 55 North Private Wealth LLC now owns 598 shares of the company’s stock worth $233,000 after purchasing an additional 26 shares in the last quarter. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Elevance Health Company Profile

Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.

The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.